I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $144.64M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
| | ||||
Ardais Corp. |
Lexington, Mass. |
2/27 |
$13.4 |
Ardais completed a Series C round, bringing in $13.4M, co-led by The Kaufmann Fund, Advanced Technology Ventures, Advent Health Care and Life Sciences, EGS Healthcare Capital Partners, Bessemer Venture Partners, Pequot Private Equity Fund, BioVentures Investors and Silicon Valley Bancshares |
|
||||
Bacterial BarCodes Inc. |
Houston |
2/12 |
$6 |
Bacterial BarCodes raised $6M in additional funding in its Series C financing, led by Techxas Ventures; other investors were Koch Ventures and Pacific Rim Ventures, as well as the Baylor College of Medicine and BioTex Finance Ltd. |
|
||||
BattellePharma Inc. |
Columbus, Ohio |
2/19 |
$22 |
BattellePharma closed a Series B venture round, raising $22M; investors were TL Ventures, Merlin BioMed Group, Fletcher Spaght Ventures LP, Richardson Ventures Inc. and Battelle Memorial Institute |
|
||||
Diatos SA |
Paris |
2/12 |
€6.5 (US$7) |
Diatos raised US$7M in a round led by Credit Lyonnais Private Equity; it was supported by Diatos' existing investors |
|
||||
Elixir Pharmaceuticals Inc. |
Cambridge, Mass. |
2/12 |
$17 |
Elixir raised $17M in the initial closing of an ongoing Series B round led by MPM Capital LP, ARCH Venture Partners and Oxford Bioscience Partners |
|
|
|||
Galileo |
Montreal |
2/25 |
C$7.7 (US$5.2) |
Galileo closed two financings totaling US$5.2M funded by HBM Bioventures, Investissement Desjardins, BTF, MVI and BioFund |
|
||||
Gene Signal |
Paris |
2/26** |
€2 (US$2.15) |
Gene Signal raised US$2.15M in an initial funding round |
|
||||
GenTel Inc. |
Madison, Wis. |
2/10 |
$1.65 |
GenTel closed a $1.65M first-round venture financing |
|
||||
Kreatech Biotechnology |
Amsterdam, the Netherlands |
2/20 |
€6 (US$6.44) |
Kreatech raised US$6.44M in its third round led by 3i plc; other investors were Life Science Partners and Alafi Capital |
|
||||
Phoqus Pharmaceuticals plc |
West Malling, UK |
2/19** |
£7 |
Phoqus raised US$11.2M in a third-round funding from Advent Venture Partners, 3i plc and Abing- worth Management Ltd. |
|
|
|||
Renovo Ltd. |
Manchester, UK |
2/5** |
£2 (US$3.3) |
Renovo raised US$3.3M in an oversubscription to its second round; investors were Temasek Holdings Pte. Ltd. and BioVeda Capital Pte. Ltd. |
|
||||
SomaLogic Inc. |
Boulder, Colo. |
2/20 |
$19.5 |
SomaLogic raised $19.5M in a Series C roundled by insiders; it included Mitsui & Co. Ltd. |
|
|
|||
Synergia |
South San Francisco |
2/11 |
$2 |
Synergia closed a $2M placement of Series A preferred stock to MPM Capital |
|
|
|||
TransTech |
High Point, N.C. |
2/4 |
$24.5 |
TransTech raised $24.5M over the past nine months through two rounds of preferred stock investments; investors were MacAndrews & Forbes Holdings, Novo Nordisk A/S and Cephalon Inc. |
|
|
|||
Vivalis SA |
Paris |
2/12** |
€3 |
Vivalis raised US$3.3M from Fonds de Co-investissements pour les Jeunes Enterprises, Creagro and Pays de Loire Developpement |
|
|
|||
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $11.48M | ||||
Company |
Partner |
Amt. (M) |
Triggering Event |
Details (Date) |
| | ||||
Astralis Ltd. (OTC BB:ASTR) |
SkyePharma plc (UK) |
$2.5 |
Investment |
Astralis received the payment as part of a December 2001 stock purchase agreement (2/3) |
|
||||
Autogen Ltd.* (Australia) |
Merck KgaA (Germany) |
A$1.4 (US$0.78) |
Milestone payment |
Autogen received the payment for work on a gene, AGT203, originally identified by Autogen (2/26**) |
|
|
|
||
Domantis Ltd.* (UK) |
Peptech Ltd. (Australia) and MVM Ltd. (UK) |
$5 |
Milestone payment |
Domantis received $5M in payments as its lead compound, an antitumor necrosis factor alpha product being co-developed with Peptech, entered preclinical testing (2/11) |
|
|
|
||
Human Genome Sciences Inc. (HGSI) |
GlaxoSmithKline plc (UK) |
ND |
Milestone payment |
Human Genome Sciences received the milestone payment for the initiation of human clinical trials of a second lipoprotein-associated phospholipase A2 inhibitor, 659032 (2/27) |
|
|
|
||
Indevus Pharmaceuticals Inc. (IDEV) |
Eli Lilly and Co. |
$2.2 |
Milestone payment |
Indevus received about $2.2M in milestone payments from Lilly as a result of the completed purchase from Lilly of the U.S. sales and marketing rights to Sarafem by Galen Holdings plc of Northern Ireland (2/10) |
|
|
|||
Isis Pharmaceuticals Inc. (ISIS) |
Amgen Inc. |
ND |
Milestone payment |
Isis achieved a research milestone in its drug discovery collaboration with Amgen (2/10) |
|
|
|
||
Myriad Genetics Inc. (MYGN) |
Abbott Laboratories Inc. |
$1 |
Milestone payment |
Myriad received the milestone payment for discovering a gene named DEP1 that causes depression (2/4) |
Pharmacopeia |
Daiichi Pharmaceutical Co. Ltd. (Japan) |
ND |
Milestone payment |
Pharmacopeia received the payment when Daiichi began preclinical development of a compound identified from the collaboration (2/3) |
Pharmacopeia |
Berlex Biosciences (U.S. affiliate of Schering AG; Germany) |
ND |
Milestone payment |
Pharmacopeia earned the milestone with Berlex's decision to continue preclinical development of a compound identified in the collaboration (2/10) |
Switch Biotech AG* (Germany) |
LEO Pharma A/S (Denmark) |
ND |
Milestone payment |
Switch earned the milestone payment for validating a target from LEO that plays a role in controlling psoriasis (2/12**) |
Tm Bioscience Corp. (Canada; VSE:TMC) |
Luminex Corp. |
ND |
Milestone payment |
Tm Bioscience received a milestone payment from Luminex related to the commercial launch of the Tm 100-based Universal Array by Luminex (2/6) |
|
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed | ||||
OTC BB = Over-the-Counter Bulletin Board; VSE = Vancouver Stock Exchange | ||||
